Pay in 4 interest-free payments of $7.04 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
For glycemic control in type 2 diabetes, the SURPASS trials showed sustained A1C reductions over 40-52 weeks across all dose levels
Vendors without established reputation in the peptide community present unknown risks
The metabolic amplification may increase both benefits and side effects
References PubMed: Physiology of GLP-1 DrugBank: GLP-1 biological role NCBI Bookshelf: Incretin hormones overview StatPearls: GLP-1 physiology [Textbook: Goodman & Gilmans The Pharmacological Basis of Therapeutics, 13th ed.]
Brand Wegovy (USA, list price): Approximately $1,349/month as of 2022
This remains speculative until detailed DXA body composition data from the Phase 3 trials becomes available
US$ 27.68
&w=538&do-not-index)
US$ 22.91
US$ 21.97
US$ 27.07
US$ 28.04
US$ 25.38
